CELSG CML 11 "ISTAHIT" Phase III Study - Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph+/BCR-ABL(+) CML Patients in Chronic Phase

Petzer, Andreas L.; Wolf, Dominik; Fong, Dominic; Bošković, Darinka; Ulmer, Hanno; Gastl, Guenther

Rezultati

eNauka > Rezultati > CELSG CML 11 "ISTAHIT" Phase III Study - Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph+/BCR-ABL(+) CML Patients in Chronic Phase

Naziv:	CELSG CML 11 "ISTAHIT" Phase III Study - Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph+/BCR-ABL(+) CML Patients in Chronic Phase
Autori:	Petzer, Andreas L.; Wolf, Dominik; Fong, Dominic; Bošković, Darinka; Ulmer, Hanno; Gastl, Guenther
Godina:	2008
Publikacija:	Blood
ISSN:	0006-4971 Blood Pretraži identifikator
Izdavač:	Orlando, FL, etc. : Grune and Stratton.
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 112 br. issue 11 str. 406-406
WoS-ID:	000262104701336
VBS COBISS:	1024773813
URI:	https://plus.cobiss.net/cobiss/sr/sr/bib/1024773813#izum.si https://enauka.gov.rs/handle/123456789/646466
M-kategorija:	Mp kategorija će biti prikazana naknadno.

Pronađi DOI

Pronalaženje DOI u servisu CrossRef-u na osnovu meta-podataka u zapisu. Prikazaće se DOI (i metapodaci) čiji se podaci najviše poklapaju. OPREZ - to ne mora biti ta publikacija.

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.